全文获取类型
收费全文 | 25564篇 |
免费 | 2543篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 203篇 |
儿科学 | 951篇 |
妇产科学 | 667篇 |
基础医学 | 3647篇 |
口腔科学 | 431篇 |
临床医学 | 3622篇 |
内科学 | 5550篇 |
皮肤病学 | 641篇 |
神经病学 | 2676篇 |
特种医学 | 602篇 |
外国民族医学 | 4篇 |
外科学 | 2522篇 |
综合类 | 212篇 |
一般理论 | 5篇 |
预防医学 | 2518篇 |
眼科学 | 313篇 |
药学 | 1668篇 |
中国医学 | 22篇 |
肿瘤学 | 1963篇 |
出版年
2023年 | 264篇 |
2022年 | 390篇 |
2021年 | 794篇 |
2020年 | 638篇 |
2019年 | 941篇 |
2018年 | 1045篇 |
2017年 | 810篇 |
2016年 | 879篇 |
2015年 | 934篇 |
2014年 | 1132篇 |
2013年 | 1521篇 |
2012年 | 1935篇 |
2011年 | 1850篇 |
2010年 | 1168篇 |
2009年 | 1055篇 |
2008年 | 1595篇 |
2007年 | 1557篇 |
2006年 | 1450篇 |
2005年 | 1356篇 |
2004年 | 1275篇 |
2003年 | 1134篇 |
2002年 | 1049篇 |
2001年 | 240篇 |
2000年 | 225篇 |
1999年 | 244篇 |
1998年 | 253篇 |
1997年 | 195篇 |
1996年 | 155篇 |
1995年 | 157篇 |
1994年 | 136篇 |
1993年 | 116篇 |
1992年 | 97篇 |
1991年 | 104篇 |
1990年 | 97篇 |
1989年 | 95篇 |
1988年 | 78篇 |
1987年 | 58篇 |
1986年 | 79篇 |
1985年 | 67篇 |
1984年 | 66篇 |
1983年 | 67篇 |
1982年 | 78篇 |
1981年 | 80篇 |
1980年 | 49篇 |
1979年 | 36篇 |
1978年 | 45篇 |
1977年 | 49篇 |
1976年 | 61篇 |
1975年 | 44篇 |
1974年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group 下载免费PDF全文
Eirini Katodritou Evangelos Terpos Charikleia Kelaidi Maria Kotsopoulou Sossana Delimpasi Marie‐Christine Kyrtsonis Argiris Symeonidis Nikos Giannakoulas Aikaterini Stefanoudaki Dimitrios Christoulas Christina Chatziaggelidou Vassiliki Gastari Nikos Spyridis Evgenia Verrou Pavlina Konstantinidou Kostas Zervas Meletios A. Dimopoulos 《American journal of hematology》2014,89(2):145-150
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezomib‐based regimens (BBR) are highly effective in myeloma, but there is limited information about their efficacy and safety in PCL. Thus, we retrospectively collected data from 42 consecutive PCL patients (25 with primary PCL‐pPCL and 17 with secondary PCL‐sPCL) to explore the role of BBR in this entity. BBR were administered in 29 of 42 patients, while 6 of 25 patients with pPCL underwent autologous transplantation. Objective response (≥partial response) was significantly higher in patients treated with BBR versus conventional therapies (69% vs. 30.8%, P = 0.04); 27.5% of patients treated with BBR achieved at least very good partial response (vgPR). The highest ORR was observed in pPCL patients treated with BBR (88.9%; ≥vgPR: 33.3%). In BBR‐group, grade 3 of 4 hematological, neurological and renal toxicity and neutropenic infections were observed in 41.4%, 7%, 3.4%, and 31%, respectively. With a median follow‐up of 51 months, median overall survival (OS) for patients treated with BBR versus conventional therapies was 13 versus 2 months (P < 0.007). Median OS of patients with pPCL and sPCL treated with BBR was 18 and 7 months, respectively (P < 0.001). In the multivariate analysis normal PLTs, treatment with BBR and high quality response were the only powerful predictors for survival. Our study carrying the longest reported median follow‐up, demonstrated that treatment of PCL with BBR induces high response rates and prolongs survival over conventional therapies, regardless of additional autologous transplantation rescue or established high risk features, with manageable toxicity. Am. J. Hematol. 89:145–150, 2014. © 2013 Wiley Periodicals, Inc. 相似文献
992.
993.
994.
995.
996.
997.
998.
999.
1000.
Murray Baron Lorinda Chung Geneviève Gyger Laura Hummers Dinesh Khanna Maureen D. Mayes Janet E. Pope Ami A. Shah Virginia D. Steen Russell Steele Solène Tatibouet Ariane Herrick Ulf Müller-Ladner Marie Hudson 《Clinical rheumatology》2014,33(2):207-214
The objectives of this study were to develop a standard classification of digital ulcers (DUs) in systemic sclerosis (SSc) for use in observational or therapeutic studies and to assess the reliability of these definitions as well as of the measurement of ulcer area. Ten North American rheumatologists with expertise in SSc reviewed multiple photos of DUs, examined four SSc subjects with DUs, and came to a consensus on the definitions for digital, active, healed, and indeterminate ulcers. These ten raters then examined the right hand of ten SSc subjects twice and the left hand once to classify ulcers and to measure ulcer area. Weighted and Fleiss kappa were used to calculate intra- and interrater agreement on classification of ulcers, and intraclass correlation coefficient (ICC) was used to assess agreement on ulcer area. Because the traditional ICC calculations relied on a small number of ulcers, ICCs were recalculated using the results of linear mixed models to evaluate the variance components of observations on all the data. Intrarater kappa for classifying DU as not an ulcer/healed ulcer versus active/indeterminate ulcer was substantial (0.76), and interrater kappa was moderate (0.53). The ICC for ulcer area using the linear mixed models was moderate both for intrarater (0.57) and interrater (0.48) measurements. A consensus for the classification of DUs in SSc was developed, and after a training session, rheumatologists with expertise in SSc are able to reliably classify DUs and to measure ulcer area. 相似文献